University of Thessaly (UTH)
Διερεύνηση του ρόλου των αυτοαντιγόνων και μηχανισμών αυτοανοσίας στην παθογένεια των ιδιοπαθών φλεγμονωδών μυοπαθειών και της ψωριασικής αρθρίτιδας
Abstract
dc:descriptionThis study examines the role of myositis-specific autoantigens and autoantibodies associated with Idiopathic Inflammatory Myopathies (IIM) in the pathogenesis of psoriatic arthritis and IIM in a Greek population. General Section An extensive literature review was conducted on myositis-specific autoantigens and autoantibodies and their potential role in the pathogenesis of autoimmune rheumatic diseases, as well as their association with specific clinical syndromes and target organ involvement. These antibodies appear to play an increasingly important role in the diagnosis of Idiopathic Inflammatory Myopathies. Antinuclear antibodies (ANA) are detected in a significant proportion of patients with psoriatic disease. However, the specific targets of ANA remain largely unknown. For this reason, it was investigated whether the myositis-specific autoantigens and autoantibodies of IIM could represent ANA targets. Experimental Section ANA are detected at high rates in the serum of patients with psoriatic disease. However, autoantibodies associated with IIM are not detected in these patients and thus do not offer diagnostic value regarding the interpretation of ANA in psoriatic disease. ANA frequency reached 40.6%, yet no reactivity was observed against any of the myositis-specific antigens and antibodies. Therefore, researchers focused on the role of these antibodies in the pathogenesis and autoimmune mechanisms of IIM. In a second phase, a literature review was conducted on cases of inflammatory myositis following COVID-19 vaccination, prompted by a case hospitalized in our clinic. In 49 identified cases (mean age 56.5 years, 59% female), 70% had received an mRNA vaccine. Muscle involvement was the most frequent manifestation (79.5%), while skin lesions and interstitial lung disease (ILD) were observed in 53% and 34.6% of cases, respectively—mostly in mRNA vaccine recipients. Treatment approaches included corticosteroids, immunoglobulins, and immunosuppressants. Although the causal relationship with vaccination remains controversial, potential pathogenic mechanisms include cross-reactivity between viral and host epitopes, molecular mimicry, and the bystander effect. The overall evaluation of cases highlights the need for systematic monitoring and epidemiological vigilance regarding new cases of myositis in the post-COVID-19 pandemic era. Lastly, the possibility of a paraneoplastic manifestation should be considered even in patients where IIM onset closely follows SARS-CoV-2 vaccination. Cohort Analysis In a cohort of 113 Greek patients with IIM (2001–2024) monitored in our hospital, cancer-associated myositis (CAM) cases were identified, recorded, and studied, accounting for 22.1% of cases. Older age and the presence of dermatomyositis were associated with CAM. A strong risk factor was the presence of anti-TIF1γ antibodies (OR: 6.9, p<0.001), while anti-Jo1 antibodies appeared protective (OR: 0.13). Gottron’s papules, heliotrope rash, and Holster sign were positively associated with CAM, whereas Raynaud’s phenomenon, ILD, and NSIP had a protective role. The most frequent malignancies were breast, ovarian, and lung cancers. The findings underscore the importance of systematic oncological screening in IIM patients. Subgroup Analysis A focused analysis of the anti-TIF1γ-positive subgroup revealed a strong association with dermatomyositis (95%) and more severe skin involvement (mean CDASI score 27.35 vs 14 in negatives, p=0.0015). Malignancy frequency was significantly higher (60% vs 20.4%, p=0.001), and survival was lower (55.7% vs 82.6%, p<0.001). Additionally, dysphagia was more frequent, whereas ILD was less common. These results establish anti-TIF1γ antibodies as markers of a distinct IIM phenotype with increased cancer risk and poor prognosis. Conclusion Overall, the study highlights the diagnostic and prognostic value of specific autoantibodies and autoantigens and emphasizes the importance of timely and individualized cancer screening in patients with IIM.
Degree
thesis:*- Grantor dc:publisher
- University of Thessaly (UTH)
- Year dc:date
- 2025
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Syrmou, Vasiliki
- Σύρμου, Βασιλική
Subjects
dc:subject × 26- Ιδιοπαθείς μυοπάθειες
- Διάμεση πνευμονική νόσος
- Μυοσίτιδα
- Παρανεοπλασματικά σύνδρομα
- Κακοήθεια
- Ειδικά αυτοαντισώματα μυοσίτιδας
- Μυοσίτιδα σχετιζόμενη με κακοήθεια
- Δερματομυοσίτις
- Idiopathic myopathies
- Myositis
- Dermatomyositis
- Interstitial lung diseases
- Paraneoplastic syndromes
- Malignancy
- Myositis-specific antibodies
- Cancer-associated myositis
- Κλινική Ιατρική
- Ιατρική και Επιστήμες Υγείας
- Ρευματολογία
- Βασική Ιατρική
- Ανοσολογία
- Clinical Medicine
- Medical and Health Sciences
- Rheumatology
- Basic Medicine
- Immunology
Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/59442